Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Novartis Delivers Influenza A Vaccine To US
Novartis has shipped over 7.5 million doses of Influenza A(H1N1) vaccine ready to use and expects 25 to 30 million doses of unadjuvanted vaccine to become available in
Novartis has shipped over 7.5 million doses of Influenza A(H1N1) vaccine ready to use and expects 25 to 30 million doses of unadjuvanted vaccine to become available in
The FDA has issued a Complete Response Letter to Transcept Pharmaceuticals (Transcept) regarding the New Drug Application (NDA) for Intermezzo (zolpidem tartrate sublingual tablet). The NDA, submitted by
Simcere Pharmaceutical (Simcere) has entered into an agreement to acquire a 74.49% stake in ChinaVax, a Cayman Islands company that, as its sole business, holds a 13.27% stake
Octapharma Group and Fresenius Kabi have signed a license, development and supply agreement regarding the use of latter’s HESylation Technology to develop a HESylated recombinant protein. Under the
Daiichi Sankyo has submitted an application in Japan to manufacture and market an injectable preparation of Levofloxacin Hydrate, that incorporates the company’s new quinolone anti-bacterial agent. Reportedly, the
Biomerica’s new facility is the result of a two-year search of possible buildings in the Orange County area. The manufacturing layouts have taken job and process flow into
Smiths Medical has been selected for a $10m contract from the US Department of Health and Human Services (HHS) for safety hypodermic syringes. The award is part of
NCKU has signed a Technology Transfer Agreement with Vedan International. The agreement marks a successful transfer of NCKU’s microalgal DHA (docosahexaenoic acid) production technology, developed by Huey-Lang Yang’s
Novarts’ biological medicine Ilaris (canakinumab) has been approved in the EU to treat adults and children as young as four years old, with cryopyrin-associated periodic syndrome (CAPS). Reportedly,
ThromboGenics and BioInvent International (BioInvent) have completed enrollment of their phase II trial of TB-402 ahead of schedule. TB-402 is a novel, long acting anticoagulant that is being